VC-backed Clementia seeks up to $150 mln from public debut
Montréal clinical-stage biopharmaceutical company Clementia Pharmaceuticals Inc has filed for an initial public offering in the United States, Reuters recently reported. The company is seeking as much as $150 million (US$115 million) from an offering of common shares on the Nasdaq Global Market. Founded in 2010, Clementia is developing treatments for patients suffering from debilitating bone and other diseases. It has raised north of US$90 million from venture capital investors, including BDC Capital, Janus Henderson Investors, OrbiMed Advisors and New Enterprise Associates.
7 July 2017•1 min read
